S Jung1, R E Schmieder2. 1. Medizinische Klinik 4 - Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen (FAU), Ulmenweg 18, 91054, Erlangen, Deutschland. 2. Medizinische Klinik 4 - Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen (FAU), Ulmenweg 18, 91054, Erlangen, Deutschland. roland.schmieder@uk-erlangen.de.
Abstract
BACKGROUND: In November 2017, the latest American guidelines for the management of arterial hypertension were published. With these guidelines lowering the threshold for hypertension to 130/80 mm Hg, the latest European guidelines were expected with excitement. OBJECTIVES: This article gives an overview on the European Society of Cardiology (ESC) and European Society of Hypertension (ESH) 2018 guidelines for the management of arterial hypertension, thereby identifying the most relevant changes in comparison to previous guidelines. CURRENT DATA: The latest 2018 ESC/ESH guidelines adhere to the previous definition of hypertension, in which a blood pressure of 140/90 mm Hg is considered as threshold for diagnosis. In contrast, there was a change in blood pressure treatment target from below 140/90 to between 120-129/70-79 mm Hg in patients < 65 years if well tolerated. Among patients ≥ 65 years, a systolic blood pressure between 130 and 139 mm Hg is recommended, whereas a diastolic blood pressure between 70 and 79 mm Hg should be targeted. Additionally the guidelines recommend the use of fixed dose combinations as first choice instead of monotherapy to improve adherence. Interventional treatment strategies should only be applied in carefully selected patients at experienced centers and are not recommended outside of clinical studies and registers. Furthermore, the chapters regarding initiation of blood pressure-lowering therapy and clinical evaluation as well as management of hypertension emergencies have been outlined. CONCLUSIONS: The latest European guidelines for the management of hypertension include several changes. One of the most important aspects is that-in contrast to the American guidelines-the threshold for diagnosis remains at 140/90 mm Hg, whereas treatment target range has been lowered by roughly 10 mm Hg and single pill fixed dose combinations are recommended.
BACKGROUND: In November 2017, the latest American guidelines for the management of arterial hypertension were published. With these guidelines lowering the threshold for hypertension to 130/80 mm Hg, the latest European guidelines were expected with excitement. OBJECTIVES: This article gives an overview on the European Society of Cardiology (ESC) and European Society of Hypertension (ESH) 2018 guidelines for the management of arterial hypertension, thereby identifying the most relevant changes in comparison to previous guidelines. CURRENT DATA: The latest 2018 ESC/ESH guidelines adhere to the previous definition of hypertension, in which a blood pressure of 140/90 mm Hg is considered as threshold for diagnosis. In contrast, there was a change in blood pressure treatment target from below 140/90 to between 120-129/70-79 mm Hg in patients < 65 years if well tolerated. Among patients ≥ 65 years, a systolic blood pressure between 130 and 139 mm Hg is recommended, whereas a diastolic blood pressure between 70 and 79 mm Hg should be targeted. Additionally the guidelines recommend the use of fixed dose combinations as first choice instead of monotherapy to improve adherence. Interventional treatment strategies should only be applied in carefully selected patients at experienced centers and are not recommended outside of clinical studies and registers. Furthermore, the chapters regarding initiation of blood pressure-lowering therapy and clinical evaluation as well as management of hypertension emergencies have been outlined. CONCLUSIONS: The latest European guidelines for the management of hypertension include several changes. One of the most important aspects is that-in contrast to the American guidelines-the threshold for diagnosis remains at 140/90 mm Hg, whereas treatment target range has been lowered by roughly 10 mm Hg and single pill fixed dose combinations are recommended.
Authors: Roland E Schmieder; Felix Mahfoud; Michel Azizi; Atul Pathak; Kyriakos Dimitriadis; Abraham A Kroon; Christian Ott; Filippo Scalise; Giuseppe Mancia; Costas Tsioufis Journal: J Hypertens Date: 2018-10 Impact factor: 4.844
Authors: Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983
Authors: Sverre E Kjeldsen; Eivind Berge; Sripal Bangalore; Franz H Messerli; Giuseppe Mancia; Björn Holzhauer; Tsushung A Hua; Dion Zappe; Alberto Zanchetti; Michael A Weber; Stevo Julius Journal: Blood Press Date: 2015-10-29 Impact factor: 2.835
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi Journal: Lancet Date: 2015-12-24 Impact factor: 79.321
Authors: Michael Böhm; Helmut Schumacher; Koon K Teo; Eva M Lonn; Felix Mahfoud; Johannes F E Mann; Giuseppe Mancia; Josep Redon; Roland E Schmieder; Karen Sliwa; Michael A Weber; Bryan Williams; Salim Yusuf Journal: Lancet Date: 2017-04-05 Impact factor: 79.321
Authors: José M Castellano; Ginés Sanz; José L Peñalvo; Sameer Bansilal; Antonio Fernández-Ortiz; Luz Alvarez; Luis Guzmán; Juan Carlos Linares; Fernando García; Fabiana D'Aniello; Joan Albert Arnáiz; Sara Varea; Felipe Martínez; Alberto Lorenzatti; Iñaki Imaz; Luis M Sánchez-Gómez; Maria Carla Roncaglioni; Marta Baviera; Sidney C Smith; Kathryn Taubert; Stuart Pocock; Carlos Brotons; Michael E Farkouh; Valentin Fuster Journal: J Am Coll Cardiol Date: 2014-09-01 Impact factor: 24.094
Authors: Johan Sundström; Hisatomi Arima; Rod Jackson; Fiona Turnbull; Kazem Rahimi; John Chalmers; Mark Woodward; Bruce Neal Journal: Ann Intern Med Date: 2015-02-03 Impact factor: 25.391
Authors: Michael Böhm; Helmut Schumacher; Koon K Teo; Eva Lonn; Felix Mahfoud; Johannes F E Mann; Giuseppe Mancia; Josep Redon; Roland Schmieder; Michael Weber; Karen Sliwa; Bryan Williams; Salim Yusuf Journal: Eur Heart J Date: 2018-09-01 Impact factor: 29.983